Clinical trials: Intravenous Infusions
Pain, Fever
Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous Ibuprofen
The primary objective of this study is to determine the safety of a single dose of intravenous ibuprofen administered over 5-10 minutes for the treatment of fever or pain in the hospital setting.
- Trial name
- NCT01334944
- Testing
- Intravenous ibuprofen
- Where
- 13 sites in United States
- Volunteers
- 150 people
- Sponsor
- Cumberland Pharmaceuticals
Diabetes, Healthy
A Trial Investigating the Relationship Between Pharmacodynamic and Interstitial Concentration for Insulin Detemir and Human Insulin
This study is conducted in Europe. The aim of this study is to estimate the relationship between pharmacodynamic and interstitial pharmacokinetic steady state following intravenous (i.v.) administration of insulin detemir and…
- Trial name
- NCT02162407
- Testing
- insulin detemir, human soluble insulin
- Where
- Austria
- Volunteers
- 13 people
- Sponsor
- Novo Nordisk A/S
Renal Disease
A Study to Assess the Pharmacokinetics of Ceftaroline in End Stage Renal Disease Patients and Matched Healthy Subjects
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of Ceftaroline in a group of patients with renal disease and matching healthy subjects with normal renal function
- Trial name
- NCT01664065
- Testing
- 200 mg Ceftaroline fosamil, 600 mg Ceftaroline fosamil
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypoplasminogenemia
A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous
These are single-patient studies with repeat-dose administration of ProMetic Plasminogen IV infusion in one adult and one child with hypoplasminogenemia.
- Trial name
- NCT03265171
- Testing
- Plasminogen (Human)
- Sponsor
- Prometic Biotherapeutics, Inc.
Complicated Urinary Tract Infections(cUTI)
Evaluation of the Safety, Tolerability and Pharmacokinetics of TUL108 for Injection in Healthy Participants (SAD/ MAD)
To evaluate the safety, tolerability and pharmacokinetics of single and multiple intravenous (IV) infusion of TUL108 in healthy participants.
- Trial name
- NCT07719257
- Testing
- TUL108
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Zhuhai United Laboratories Co., Ltd.
Healthy Volunteers
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Atrosimab (ATM001) in Healthy Volunteers
This is a double-blind, parallel group and placebo-controlled clinical study to assess safety tolerability, pharmacokinetics and pharmacodynamics of Atrosimab in healthy volunteers
- Trial name
- NCT04650126
- Testing
- ATM001
- Where
- Australia
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Baliopharm Pty Ltd
Chronic Plaque Psoriasis
A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis
Comparison of two dosing regimens of Alefacept in subjects weighing between 100kg and 150kg with moderate to severe Chronic Plaque Psoriasis
- Trial name
- NCT00674063
- Testing
- alefacept
- Where
- 17 sites in United States, Canada
- Volunteers
- 78 people
- Sponsor
- Astellas Pharma Inc
Drug Drug Interaction
Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects
To evaluate the effect of coadministered cyclosporine on the pharmacokinetics of brincidofovir following simultaneous administration of SyB V-1901 with cyclosporine, or coadministration of cyclosporine at 2 hours after the…
- Trial name
- NCT04542252
- Testing
- SyB V-1901, Cyclosporine
- Where
- Japan
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- SymBio Pharmaceuticals
Idiopathic Hypersomnia
A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia
The purpose of this study is to evaluate the safety and tolerability of administering a single intravenous (IV) infusion dose of TAK-925 to adult participants with idiopathic hypersomnia (IH).
- Trial name
- NCT04091438
- Testing
- TAK-925
- Where
- 22 sites in United States, Japan
- Volunteers
- 28 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Primary Immune Deficiency Disorder
Gamma Globulin Observations and Outcomes Database for Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI)
Primary: Demonstrate the utility of an electronic data capture (EDC) system (CareExchange™) using infusion nurse and patient measured physical, quality of life (QOL), respiratory, laboratory, and disability assessments in…
- Trial name
- NCT01883921
- Testing
- Immunoglobulin Therapy
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- BriovaRx Infusion Services
Atrial Flutter
Cardiac Electrophysiological Study
The purpose of the study is to measure the effects of AZD1305 on cardiac electrophysiological properties and intracardiac pressures
- Trial name
- NCT00616629
- Testing
- AZD1305
- Where
- 13 sites in Denmark, Finland and 2 more
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Lymphoma, Non-Hodgkin
SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma
The primary objective is to determine the maximum tolerated dose (MTD) of SAR3419 according to the dose limiting toxicities (DLTs) observed when administered as a single agent once weekly.
- Trial name
- NCT00796731
- Testing
- SAR3419
- Where
- 6 sites in France
- Volunteers
- 77 people
- Sponsor
- Sanofi
Lupus Erythematosus, Systemic
SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)
To collect information on and evaluate the long-term safety and effectiveness of Anifrolumab in patients with systemic lupus erythematosus in the real-world post-marketing setting.
- Trial name
- NCT05141201
- Where
- 47 sites in Japan
- Volunteers
- 1,620 people
- Sponsor
- AstraZeneca
Cerebrovascular Accident
A Study to Evaluate the Effects of ONO-2506 Intravenous Infusion in Patients With Acute Ischemic Stroke
The primary objective of this study is to compare the efficacy of ONO-2506 versus placebo in neurological stroke outcome in patients with acute ischemic stroke.
- Trial name
- NCT00046761
- Testing
- ONO-2506
- Where
- 148 sites in United States, Canada
- Volunteers
- 1,320 people
- Sponsor
- Ono Pharma USA Inc
Healthy
Tolerability and Pharmacokinetics/-Dynamics of Single Rising Doses BIBT 986 BS in Healthy Male Subjects
Study to assess the tolerability of BIBT 986 BS after intravenous infusions of 0.1, 0.3, 1.0, 2.5, 5.0, and 10 mg, to assess the pharmacokinetics of BIBT 986 BS after intravenous infusion and to assess the effect of BIBT 986 BS…
- Trial name
- NCT02254057
- Testing
- BIBT 986 BS - single rising dose
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Drug Interaction
Phase 1 Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion With Clopidogrel in Healthy Subjects
This study is being conducted to test the hypothesis that coadministration of clopidogrel with DS-1040b will be safe and well tolerated.
- Trial name
- NCT02560688
- Testing
- DS-1040b, Clopidogrel
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo
Small Cell Lung Carcinoma (SCLC)
DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer
This study is open to adults with extensive stage small cell lung cancer. The study is in people with advanced cancer that are eligible for standard of care including chemotherapy and anti-PD-L1 (Programmed Cell Death Ligand 1)…
- Trial name
- DAREONᵀᴹ-8 (NCT06077500)
- Testing
- BI 764532, Carboplatin, Etoposide
- Where
- 21 sites in United States, Belgium and 6 more
- Volunteers
- 46 people
- Sponsor
- Boehringer Ingelheim
Ischemic Stroke
Safety and Pharmacokinetics of Multiple Dose of YC-6 in Healthy Subjects
The study is designed to determine the safety, tolerability, and pharmacokinetics in healthy subjects with multiple intravenous administration of the neuroprotectant YC-6 compared to placebo.
- Trial name
- NCT03358901
- Testing
- YC-6, Vehicle
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Guangzhou Cellprotek Pharmaceutical Co., Ltd.
Healthy Subjects (HS), SLE (Systemic Lupus)
First-in-Human Study of ISH0613: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics
The goal of this clinical trial is to learn about a study drug called ISH0613 and how it behaves in healthy adults. This study will also evaluate the safety and tolerability of ISH0613 after a single intravenous (IV) dose.
- Trial name
- NCT07516639
- Testing
- ISH0613 for injection
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Pompe Disease
First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221
This is an international, multi-center, open-label study designed to evaluate if the co-administration of investigational new drugs ATB200 and AT2221 is safe in adults with Pompe disease.
- Trial name
- NCT02675465
- Testing
- ATB200, AT2221
- Where
- 19 sites in United States, Australia and 4 more
- Volunteers
- 29 people
- Sponsor
- Amicus Therapeutics